Literature DB >> 20304954

MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma.

Jiamin Chen1, Harriet E Feilotter, Geneviève C Paré, Xiao Zhang, Joshua G W Pemberton, Cherif Garady, Dulcie Lai, Xiaolong Yang, Victor A Tron.   

Abstract

Cutaneous melanoma is an aggressive form of human skin cancer characterized by high metastatic potential and poor prognosis. To better understand the role of microRNAs (miRNAs) in melanoma, the expression of 470 miRNAs was profiled in tissue samples from benign nevi and metastatic melanomas. We identified 31 miRNAs that were differentially expressed (13 up-regulated and 18 down-regulated) in metastatic melanomas relative to benign nevi. Notably, miR-193b was significantly down-regulated in the melanoma tissues examined. To understand the role of miR-193b in melanoma, functional studies were undertaken. Overexpression of miR-193b in melanoma cell lines repressed cell proliferation. Gene expression profiling identified 314 genes down-regulated by overexpression of miR-193b in Malme-3M cells. Eighteen of these down-regulated genes, including cyclin D1 (CCND1), were also identified as putative miR-193b targets by TargetScan. Overexpression of miR-193b in Malme-3M cells down-regulated CCND1 mRNA and protein by > or = 50%. A luciferase reporter assay confirmed that miR-193b directly regulates CCND1 by binding to the 3'untranslated region of CCND1 mRNA. These studies indicate that miR-193b represses cell proliferation and regulates CCND1 expression and suggest that dysregulation of miR-193b may play an important role in melanoma development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20304954      PMCID: PMC2861116          DOI: 10.2353/ajpath.2010.091061

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

1.  Significance analysis of microarrays applied to the ionizing radiation response.

Authors:  V G Tusher; R Tibshirani; G Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

Review 2.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

3.  Mitogen-actived protein kinase activation is an early event in melanoma progression.

Authors:  Cynthia Cohen; Angel Zavala-Pompa; Judy H Sequeira; Mamoru Shoji; Deborah G Sexton; George Cotsonis; Francesca Cerimele; Baskaran Govindarajan; Nada Macaron; Jack L Arbiser
Journal:  Clin Cancer Res       Date:  2002-12       Impact factor: 12.531

Review 4.  Melanoma incidence trends.

Authors:  Caroline Bevona; Arthur J Sober
Journal:  Dermatol Clin       Date:  2002-10       Impact factor: 3.478

5.  Expression profile of mammalian microRNAs in endometrioid adenocarcinoma.

Authors:  Weiguang Wu; Zhongqiu Lin; Zhiqiang Zhuang; Xinjun Liang
Journal:  Eur J Cancer Prev       Date:  2009-02       Impact factor: 2.497

6.  Expression of apoptosis regulators in cutaneous malignant melanoma.

Authors:  L Tang; V A Tron; J C Reed; K J Mah; M Krajewska; G Li; X Zhou; V C Ho; M J Trotter
Journal:  Clin Cancer Res       Date:  1998-08       Impact factor: 12.531

7.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

8.  High frequency of BRAF mutations in nevi.

Authors:  Pamela M Pollock; Ursula L Harper; Katherine S Hansen; Laura M Yudt; Mitchell Stark; Christiane M Robbins; Tracy Y Moses; Galen Hostetter; Urs Wagner; John Kakareka; Ghadi Salem; Tom Pohida; Peter Heenan; Paul Duray; Olli Kallioniemi; Nicholas K Hayward; Jeffrey M Trent; Paul S Meltzer
Journal:  Nat Genet       Date:  2002-11-25       Impact factor: 38.330

9.  Loss of E-cadherin leads to upregulation of NFkappaB activity in malignant melanoma.

Authors:  S Kuphal; I Poser; C Jobin; C Hellerbrand; A K Bosserhoff
Journal:  Oncogene       Date:  2004-11-04       Impact factor: 9.867

10.  Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas.

Authors:  G M Maelandsmo; V A Flørenes; E Hovig; T Oyjord; O Engebraaten; R Holm; A L Børresen; O Fodstad
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

View more
  98 in total

1.  Identification of miR-193b targets in breast cancer cells and systems biological analysis of their functional impact.

Authors:  Suvi-Katri Leivonen; Anne Rokka; Päivi Ostling; Pekka Kohonen; Garry L Corthals; Olli Kallioniemi; Merja Perälä
Journal:  Mol Cell Proteomics       Date:  2011-04-21       Impact factor: 5.911

Review 2.  MicroRNAs in skin and wound healing.

Authors:  Jaideep Banerjee; Yuk Cheung Chan; Chandan K Sen
Journal:  Physiol Genomics       Date:  2010-10-19       Impact factor: 3.107

3.  Maternal obesity downregulates microRNA let-7g expression, a possible mechanism for enhanced adipogenesis during ovine fetal skeletal muscle development.

Authors:  X Yan; Y Huang; J-X Zhao; C J Rogers; M-J Zhu; S P Ford; P W Nathanielsz; M Du
Journal:  Int J Obes (Lond)       Date:  2012-05-22       Impact factor: 5.095

Review 4.  The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma.

Authors:  Muhammad Nauman Aftab; Marcel E Dinger; Ranjan J Perera
Journal:  Arch Biochem Biophys       Date:  2014-07-24       Impact factor: 4.013

Review 5.  miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma.

Authors:  Paige E Bennett; Lynne Bemis; David A Norris; Yiqun G Shellman
Journal:  Physiol Genomics       Date:  2013-09-17       Impact factor: 3.107

Review 6.  Molecular and cellular pathogenesis of melanoma initiation and progression.

Authors:  Tarik Regad
Journal:  Cell Mol Life Sci       Date:  2013-03-27       Impact factor: 9.261

Review 7.  Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule.

Authors:  Antonella Chillemi; Gianluca Zaccarello; Valeria Quarona; Manuela Ferracin; Chiara Ghimenti; Massimo Massaia; Alberto L Horenstein; Fabio Malavasi
Journal:  Mol Med       Date:  2013-05-20       Impact factor: 6.354

8.  Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies.

Authors:  Luca Sigalotti; Alessia Covre; Elisabetta Fratta; Giulia Parisi; Francesca Colizzi; Aurora Rizzo; Riccardo Danielli; Hugues J M Nicolay; Sandra Coral; Michele Maio
Journal:  J Transl Med       Date:  2010-06-11       Impact factor: 5.531

9.  Translational control of cyclins.

Authors:  Woan-Yuh Tarn; Ming-Chih Lai
Journal:  Cell Div       Date:  2011-02-11       Impact factor: 5.130

10.  MicroRNA gene dosage alterations and drug response in lung cancer.

Authors:  Katey S S Enfield; Greg L Stewart; Larissa A Pikor; Carlos E Alvarez; Stephen Lam; Wan L Lam; Raj Chari
Journal:  J Biomed Biotechnol       Date:  2011-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.